Table 3.
Univariable analysis with time-dependent Cox proportional hazard regression.
| Variables # | Total person-time intervals | Time-dependent HR (95% CI) | p-value |
|---|---|---|---|
| CRP | 1327 | 1.01 (1.00, 1.02) | 0.024* |
| CRP >3 mg/l | 1327 | 2.71 (1.12, 6.51) | 0.026* |
| ESR | 1272 | 1.01 (1.00, 1.02) | 0.045* |
| MTX | 1618 | 1.16 (0.56, 2.40) | 0.681 |
| NSAIDs | 1618 | 0.41 (0.19, 0.88) | 0.022* |
| COX2 selective inhibitor | 0.82 (0.11, 6.14) | 0.850 | |
| Non-COX2 selective inhibitor | 0.44 (0.21, 0.96) | 0.038* | |
| Diclofenac | 0.76 (0.35, 1.67) | 0.490 | |
| Naproxen | 0.19 (0.03, 1.47) | 0.114 | |
| Sulindac | 1.04 (0.14, 7.62) | 0.972 | |
| Ibuprofen | 0.00 (0.00, ∞) | 0.997 | |
| Mefanamic acid | 0.00 (0.00, ∞) | 0.997 | |
| Indomethacin | 0.00 (0.00, ∞) | 0.997 | |
| Piroxicam | 0.00 (0.00, ∞) | 0.997 | |
| bDMARDs | 1618 | 0.72 (0.22, 2.38) | 0.591 |
| Lipid-lowering drugs | 1618 | 1.22 (0.49, 3.05) | 0.675 |
| Anti-diabetic drugs | 1618 | 1.75 (0.77, 3.94) | 0.180 |
| Anti-hypertensive drugs | 1618 | 1.60 (0.69, 3.74) | 0.276 |
| FRS at baseline | N/A | 6.89 (2.59, 18.33) | <0.001* |
#
Variables are time-varying unless otherwise specified.
*
Statistically significant at p ⩽ 0.05.
bDMARD, biological disease-modifying anti-rheumatic drug; CI, confidence interval; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FRS, Framingham risk score; HR, hazard ratio; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug.